Haydale launches graphene-enhanced cooling fluid for data centers

Published 30/10/2025, 11:50
Haydale launches graphene-enhanced cooling fluid for data centers

LONDON - Haydale Graphene Industries plc (AIM:HAYD) announced Thursday the launch of a graphene-enhanced heat-transfer fluid, expanding its commercial platform into the cooling and thermal management market.

The advanced materials group has received a Notice of Intention to Grant from the UK Intellectual Property Office for patent GB 2625980, which covers the use of surface-functionalised graphene particles in heat-transfer fluids for heating and cooling systems.

To accelerate commercial deployment, Haydale has formed a strategic partnership with Liquitherm Technologies Group, a UK-based formulator of specialist heat-transfer fluids with over 25 years of experience, to jointly commercialize the patented technology across domestic, industrial and data-center applications.

The company has also received a non-binding Letter of Intent from a US-based global manufacturer of electric vehicles and energy systems to evaluate the fluid for next-generation power-device cooling.

Additionally, Haydale signed two Memoranda of Understanding with UK data-center design specialists to trial the fluid within cooling systems in South Wales and other UK locations.

The development represents the second key pillar in Haydale’s commercialization strategy, following its JustHeat product line. The company’s technology aims to address heat dissipation challenges in data centers and high-performance computing facilities, where cooling can account for up to 40 percent of total power consumption.

Simon Turek, CEO of Haydale, stated: "From graphene to gigawatts, South Wales is quietly building the materials engine of the modern digital economy, and Haydale is proud to be contributing at its centre."

The company noted that while these agreements are not expected to generate immediate commercial revenues, they represent the next phase in commercializing the technology as it moves from laboratory validation into controlled field trials with partners.

The announcement was based on a company press release.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.